| Autor: |
Kootte, Antoinette M. M., Henny, Felix C., Moolenaar, Abraham J., Dijkmans, Ben A. C., Es, Leendert A., Paul, Leendert C. |
| Zdroj: |
Clinical Transplantation; December 1988, Vol. 2 Issue: 6 p319-323, 5p |
| Abstrakt: |
Serial serum β2 microglobulin (β2M) levels were measured in 50 renal transplant patients on different immunosuppressive regimens as well as in 5 patients with rheumatoid arthritis treated with cyclosporine‐A (CsA). Since the glomerular filtration rate determines the level of serum β2M, the measured level was compared to the expected level using the formula: Log, β2M (mg/l) = 3.834–5.96y + 2.94 y2–0.476 y3+ 0.0252 y4, where y represents Logcserum creatinine (mg/l). The median value of the observed/expected ratios per patient in groups of renal patients with or without rejection was used for data analysis; no differences were found for patients on azathioprine with or without rejection episodes and CsA‐treated patients without rejection episodes (range 0.52–3.94), including patients with CsA nephrotoxicity or CMV infections. In CsA‐treated patients who experienced acute rejection episodes the ratios were lower compared with all other groups (range 0.28–0.92) (p < 0.05). The fractional excretion (FE) of β2M in the CsA‐treated patients prior to or during periods of graft rejection (n = 5) was higher than in CsA‐treated patients without rejection episodes (n = 6) (6%–91% and 0.8%–12.6%, respectively). The relatively low serum β2M level in the CsA‐treated renal transplant patients with rejection episodes may reflect a tubular dysfunction induced by the combined effects of rejection and CsA resulting in an urinary β2M leak. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
